Another win for Novo's semaglutide? Physicians prefer it most in the emerging field of NASH treatments, survey finds
As fatty liver disease gets a new name, will it also finally get approved drug treatments?
That’s what healthcare professionals are hoping for as nonalcoholic fatty liver disease (NAFLD) becomes metabolic dysfunction-associated steatotic liver disease (MASLD), and nonalcoholic steatohepatitis (NASH) becomes metabolic dysfunction-associated steatohepatitis (MASH). The name changes, aimed at getting rid of stigmatizing language like “fatty liver,” are set to be fully rolled out later this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.